Wacker Chemie AG Financial Results H1 2025 | Lower Earnings, Solid Liquidity, and Updated Outlook

Wacker Chemie AG H1 2025: Key TakeawaysWacker Chemie AG: Q2 2025 Financial ResultsPresented by Joerg Hoffmann, CFA – Head of Investor RelationsIn this detailed financial update, Joerg Hoffmann, CFA, Head of Investor Relations at Wacker Chemie AG, presents the company’s performance for Q2 2025. While the group navigates persistent macroeconomic headwinds, FX volatility, and softer demand, Wacker remains strategically focused and financially stable with a strong balance sheet and proactive measures to improve profitability.📊 Q2 2025 Financial Summary:Metric      Q2 2025   Q2 2024   YoY ChangeSales       €1.41bn    €1.47bn    -4%EBITDA      €114m    €155m    -26%EBIT        -€11m    €38m    n.a.Net Income    -€19m    €35m    n.a.EBITDA Margin   8.1%    10.5%CapEx       €96m    €177m    -46%Net Financial Debt €1.14bn   €661m    +72%Joerg Hoffmann attributed the earnings decline primarily to weak volume and pricing effects, unfavourable FX developments, and a planned turnaround in Polymers. Additionally, elevated working capital and dividend payments contributed to the higher net debt.🌍 Strategic Context & Outlook:Due to continued geopolitical uncertainty, trade-related volatility, and a challenging global economic environment, Wacker has lowered its full-year 2025 guidance:Sales now expected between €5.5–5.9 billion (previously €6.1–6.4 billion)EBITDA expected between €500–700 million (down from €700–900 million)To address these challenges, Wacker is implementing a 3-part strategy:Growth: Intensify sales and innovation focusCash: Optimise working capital and reduce investmentCost: Improve productivity and utilisation rates across sites🔬 Segment Performance Highlights:🧪 SiliconesSales: €713m | EBITDA: €104mVolumes higher YoY, but pricing and FX impacts continuedSupported by insurance compensation for supply chain disruptionsFY outlook: sales and EBITDA at prior-year level🧱 PolymersSales: €363m | EBITDA: €40mWeaker construction demand in Europe and ChinaVAM turnaround impacted resultsFY outlook: slight sales decline, stable margins🧫 BiosolutionsSales: €87m | EBITDA: €5mMarket softness continued, though the BENEO partnership for human milk oligosaccharides was initiatedFY outlook: stable sales and EBITDA☀️ PolysiliconSales: €218m | EBITDA: €34mStrong semi-grade sales, but solar volumes down due to U.S. tariffs and policy uncertaintyFocus remains on cost and cash managementFY outlook: flat sales, EBITDA ~€100m💰 Balance Sheet & Liquidity:Equity: €4.5bn (down €335m due to FX and dividend)Liquidity: €796m cash and securitiesCapEx: €96m in Q2, aligned with strategic spend reductionPension liabilities: reduced to €692mWacker’s financial health remains strong, with ample liquidity, although net debt rose to support dividends and investments.🌱 Sustainability & ESG Progress:Product carbon footprints (PCFs) are now provided to customersProgress in reducing CO₂e emissions, water, and energy consumptionTargets remain in place for Net Zero by 2045Continued focus on diversity, supplier sustainability, and safety🔭 Outlook & Key Message from Joerg Hoffmann:▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.